X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1576) 1576
Patent (1402) 1402
Conference Proceeding (98) 98
Book Review (37) 37
Publication (32) 32
Book Chapter (4) 4
Technical Report (3) 3
Book / eBook (2) 2
Dissertation (1) 1
Newspaper Article (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (689) 689
humans (562) 562
performing operations (486) 486
transporting (486) 486
electricity (405) 405
male (403) 403
oncology (391) 391
female (381) 381
physics (339) 339
chemistry (320) 320
metallurgy (315) 315
middle aged (310) 310
basic electric elements (299) 299
general tagging of cross-sectional technologies spanning over several sections of the ipc (282) 282
general tagging of new technological developments (282) 282
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (282) 282
aged (281) 281
heating (258) 258
lighting (258) 258
blasting (257) 257
mechanical engineering (257) 257
weapons (257) 257
adult (198) 198
lung neoplasms - drug therapy (190) 190
electric solid state devices not otherwise provided for (184) 184
semiconductor devices (184) 184
chemotherapy (160) 160
animals (157) 157
technologies or applications for mitigation or adaptation againstclimate change (154) 154
carcinoma, non-small-cell lung - drug therapy (151) 151
working of plastics (149) 149
working of substances in a plastic state, in general (149) 149
technical subjects covered by former uspc (138) 138
technical subjects covered by former us classification (128) 128
cancer (125) 125
after-treatment of the shaped products, e.g. repairing (124) 124
shaping of material in a plastic state, not otherwise providedfor (124) 124
shaping or joining of plastics (124) 124
lung neoplasms - pathology (123) 123
human necessities (120) 120
treatment outcome (108) 108
antineoplastic combined chemotherapy protocols - therapeutic use (103) 103
hygiene (100) 100
medical or veterinary science (100) 100
testing (98) 98
electric communication technique (97) 97
measuring (97) 97
mice (94) 94
compositions based thereon (91) 91
organic macromolecular compounds (91) 91
their preparation or chemical working-up (91) 91
combustion engines (90) 90
hot-gas or combustion-product engine plants (90) 90
non-small cell lung cancer (88) 88
vehicles in general (85) 85
cinematography (84) 84
electrography (84) 84
holography (84) 84
photography (84) 84
analysis (83) 83
carcinoma, non-small-cell lung - pathology (83) 83
japan (83) 83
calculating (82) 82
computing (82) 82
counting (82) 82
controlling combustion engines (76) 76
lung cancer (76) 76
aged, 80 and over (73) 73
care and treatment (72) 72
producing particular articles from plastics or from substancesin a plastic state (71) 71
surgery (71) 71
gefitinib (70) 70
layered products (70) 70
layered products, i.e. products built-up of strata of flat ornon-flat, e.g. cellular or honeycomb, form (70) 70
pharmacology & pharmacy (70) 70
climate change mitigation technologies related totransportation (69) 69
lung cancer, non-small cell (69) 69
engineering elements and units (68) 68
general measures for producing and maintaining effectivefunctioning of machines or installations (68) 68
mutation (68) 68
organic chemistry (68) 68
thermal insulation in general (67) 67
lung neoplasms - genetics (66) 66
antineoplastic agents - therapeutic use (65) 65
respiratory system (65) 65
investigating or analysing materials by determining theirchemical or physical properties (64) 64
optics (64) 64
research (64) 64
prognosis (63) 63
diagnosis (61) 61
expression (61) 61
identification (61) 61
neoplasm staging (61) 61
indexing scheme associated with subclasses b29b, b29c or b29d, relating to moulding materials (60) 60
medicine & public health (60) 60
gastroenterology & hepatology (57) 57
carcinoma, non-small-cell lung - genetics (56) 56
ferrous or non-ferrous alloys (56) 56
therapy (56) 56
tumors (56) 56
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2882) 2882
French (231) 231
German (194) 194
Japanese (149) 149
Chinese (90) 90
Korean (16) 16
Portuguese (10) 10
Spanish (10) 10
Italian (4) 4
Arabic (1) 1
Indonesian (1) 1
Russian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, Issue suppl_5, pp. v7 - v7
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2017, Volume 12, Issue 5, pp. e0177133 - e0177133
Objective To compare radical surgery with definitive chemoradiation (CRT) for esophageal squamous cell carcinoma using propensity score (PS) matching at our... 
PHASE-III TRIAL | 5-FLUOROURACIL | THORACIC ESOPHAGUS | CISPLATIN | MULTIDISCIPLINARY SCIENCES | RANDOMIZED-TRIAL | CHEMORADIOTHERAPY | FLUOROURACIL | CANCER | RADIATION-THERAPY | PLUS | Humans | Middle Aged | Carcinoma, Squamous Cell - therapy | Carcinoma, Squamous Cell - surgery | Male | Chemoradiotherapy | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Esophageal Neoplasms - surgery | Survival Analysis | Aged, 80 and over | Female | Aged | Esophageal Neoplasms - therapy | Esophageal Squamous Cell Carcinoma | Care and treatment | Chemotherapy, Combination | Usage | Research | Comparative analysis | Radiotherapy | Esophageal cancer | Downloading | 5-Fluorouracil | Toxicity | Indication | Mucosa | Radiation | Clinical trials | Oncology | Cancer therapies | Personal computers | Ethics | Ultrasonic imaging | Format | Endoscopes | Computed tomography | Clavicle | Intestine | Surgery | Classification | Tomography | Endoscopy | Dissection | Ultrasound | Public health | Esophageal carcinoma | Squamous cell carcinoma | Positron emission | Thorax | Radiation therapy | Patients | Survival | Cisplatin | Radiation dosage | Esophagus | Chemotherapy | Side effects | Mail | Computation | Medical prognosis | Radiology | Irradiation | Gastrointestinal surgery | Cancer | Index Medicus
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 99, pp. 186 - 193
Journal Article
Cancer Science, ISSN 1347-9032, 03/2019, Volume 110, Issue 3, pp. 1012 - 1020
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 23, pp. JCO.19.00767 - 2090
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | GEFITINIB | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article